Europe Brain Cancer Diagnostic Market – Industry Trends and Forecast to 2030

Europe Brain Cancer Diagnostic Market Analysis and Size

One of the primary factors driving the growth of the brain cancer diagnostic market is the rising cases of brain cancer worldwide. The continuing clinical trial research being conducted by several companies for better treatment leads to market expansion. The market is also influenced by rising awareness of the early diagnosis of brain cancer and innovations in drug delivery to brain cancer cells. However, the high cost associated with diagnosis & treatment for brain cancer, late diagnosis of brain cancer resulting in poor prognosis, and side-effects of treatment drugs & therapies acts as a restraining factor for the Europe brain cancer diagnostic market in the forecast period.

On the other hand, increasing investments and funding by emerging players, government initiatives towards cancer diagnostics and rising healthcare expenditure act as an opportunity for the growth of the market. However, stringent regulatory requirements for diagnostics products and operational barriers faced in conducting diagnostics tests create challenges for the Europe brain cancer diagnostic market.

The demand for brain cancer diagnostics products will increase Europe, owing to improved imaging techniques. Various companies are taking initiatives that gradually lead to the growth of the market.

The Europe Brain cancer diagnostic market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 18.2% in the forecast period of 2023 to 2030 and is expected to reach USD 1,910.94 million by 2030, from USD 503.02 million in 2022.

Market Definition

Brain cancer is an overgrowth of cells in the brain that forms masses called tumors. It is a brain disorder in which cancer cells (malignant cells) arise in the brain tissue. Cancer cells multiply to produce a mass of cancer tissue (tumor) that interferes with brain functions such as muscle control, sensation, memory, and other body functions. Cancer cells that arise from brain tissue are called primary brain tumors, while tumors that spread from other body parts to the brain are called metastatic or secondary brain tumors.

Primary brain tumors can develop from various brain tissues (for example, glial cells, astrocytes, and other brain cell types). Metastatic brain cancer is caused by the spread of cancer cells from a body organ to the brain.

Europe Brain Cancer Diagnostic Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

• Rising Cases of Brain Cancer Worldwide

Cancer that develops elsewhere in the body & then spreads into the brain is called a secondary brain tumor or brain metastasis. There are various cancers that can metastasize into the brain, such as breast cancer, lung cancer, colon cancer and kidney cancer. Brain cancer cells generally do not spread beyond the brain. Rather, they have the capacity to travel short distances within the brain. Genetic links inherited through family ancestors, chemical exposure to certain industrial chemicals or solvents, compromised immune system, and previous radiation treatments can be some of the major causes of brain cancer.

Brain cancer cases are rising worldwide. In 2019, as per the National Cancer Institute report, there were an estimated 176,566 people found living with brain & other nervous system cancer in the United States. In addition, based on 2017-2019 data, it has been predicted that approximately 0.6 percent of men & women will be diagnosed with brain and other nervous system cancer at some point during their lifetime.

• Rising awareness of the early diagnosis of brain cancer

Brain cancer awareness month is nationally recognized in the United States during the month of May. This awareness month focuses on bringing together the brain tumor community to increase awareness among the patient population.

Brain cancer is not a common type of cancer like other types. However, the need for new & innovative ways to treat brain cancer is more important. As per research studies, 1.4 million patients worldwide are suffering from malignant brain tumors & another 2, 56,000 people will be diagnosed with a malignant brain tumor by the end of the year.

The importance of patient care, education & cancer research is becoming more apparent due to the impact of COVID-19 worldwide. Considering the future perspectives, there is still more groundwork to be done to discover new drugs & effective approaches for brain cancer patients. Brain cancer awareness month is a movement that is fully dedicated to these efforts and even in the midst of a pandemic.

Opportunities

• Increasing investment and funding by emerging players

The market for brain cancer is huge, and the rising number of the population affected by this disease is attracting other players to work in the diagnostic field for this disease. Diagnosis of brain cancer in the early stage is a tedious task but can be possible with the new product line for the diagnosis of disease.

The industry offers numerous growth opportunities. Thus, a number of start-ups providing innovative products and technologies have been entering the market. Many new companies and start-ups are looking forward to the field of brain cancer. They are trying to make business expansion and increase the distribution of their newly marketed product. Some of the company are listed below and is expected to act as an opportunity for a brain cancer diagnosis.

• Government initiatives toward cancer diagnostics

The government plays a major role while taking the initiative for cancer diseases because cancer is a leading disease across the globe. Cancer has increased very briskly in people in past decades. There were 9,555,027 cases of deaths attributable to Europe cancers in 2018, of which 241,037 (2.71%) belonged to brain cancers.

The government all around the globe is actively engaged in taking several initiatives towards cancer, specifically brain cancer diagnostics, in order to increase awareness among the people regarding the cancerous disease. Government and Nongovernment organizations funded 57% of therapy-oriented biology and drug development, with 7% to prevention and 13% to early detection, diagnosis and prognosis of cancer disease. These government initiatives towards cancer diagnostics are boosting the demand of the market.

Restraints/Challenges

High cost associated with diagnosis & treatment for brain cancer

The brain is the most important part of our body, the organ which generates our memories and emotions, as well as containing our skills and expertise. Therefore, cancer of the brain is uniquely destructive. The changes a brain tumor can cause in cognition, behavior and personality result in high economic costs, which are borne by individuals, health systems (direct medical costs) and the wider public purse (direct non-medical costs and indirect costs).

The average cost of brain tumor surgery in western countries is very high. The costs associated with each type of treatment will vary depending on the specific procedure, location, and tumor severity. A study published in the journal Cancer found that brain cancer patients and their families bore a significantly higher economic burden than those affected by other types of cancer. Brain cancer patients had the highest indirect costs, at an average of USD 64,790 per year. Hence, the high cost associated with the diagnosis & treatment of brain cancer may restrain the market growth.

• Operational Barriers Faced in Conducting Diagnostics Tests

Recent advances in the field of brain cancer diagnostics may be related to the kits, instruments, reagents, control or any other. It is not easy to change the adaptability of healthcare professionals with advancement. In order to make the structural decisions and précised results in diagnostics, organizations need to conduct a training session for the healthcare professionals to overcome and avoid errors in diagnosis.     

Rural, developing, and low-income countries in the different regions do not have enough infrastructure to maintain the new kits and for the sample storage as well. This is because of the limited supply of electricity and lack and education and awareness among healthcare professionals in the handling of new kits and reagents. This leads to errors in the diagnosis results and can lead to certain deaths, and can become a threat to the carrier of the individual performing the test.

These barriers related to conducting the cancer diagnostics test may affect the life of the populations. This is one of the most difficult parts to overcome with respect to low-income countries. Thus, this is affecting the diagnostics community and acting as a challenge for the Europe brain cancer diagnostic market.

Post-COVID-19 Impact on the Europe Brain Cancer Diagnostic Market

The COVID-19 pandemic had a great impact on the brain cancer diagnostics and surgical industries. Trade groups in the cancer diagnostic products sector claim that the Europe supply chain for diagnostic products has been significantly damaged, impacting end-user consumption of the brain cancer diagnostic market. Sales of diagnostics products in the first quarter of 2020 were significantly delayed due to logistical and transportation issues. On the demand side, the market is increasing as people have to get diagnosed after the lockdown scenario. The situation needs to be taken into consideration, and emergency diagnostics need to be done. Furthermore, on the supply side, the growth of the market is on a negative scale. This is due to the lockdown situations in many countries manufacturing diagnostic, operating and cancer care instruments.

The supply of diagnostic products has suffered a massive hit due to the Europe pandemic of COVID-19. This reduction in supply is mainly due to various quarantine policies adopted by countries worldwide. This, along with the restrictions of movement and labor reduction, are the major reasons for a decreasing trend in the supply market of diagnostic instrument tracking systems. This has affected the quality and efficacy of medical devices a great deal. The existing product exportation policies of many countries have misbalanced the supply to demand ratio. Reduction in the headcount of the labor force due to COVID-19 affliction is another factor contributing to the reduced supply of brain cancer diagnostics products.

Recent Developments

• In November 2022, Siemens Healthcare GmbH has presented its two latest magnetic resonance tomographs designed for clinical and scientific use. Due to their high field strengths and strong gradient performance, both scanners will be optimal for detecting the finest structures in the body more clearly.
• In November 2022, BD has announced to grant USD 652,000 to Valley-Mount Sinai Comprehensive Cancer Care to increase diversity, equity and inclusion in cancer clinical trials.

Europe Brain Cancer Diagnostic Market Scope

The Europe brain cancer diagnostic market is segmented into test type, cancer type, age group and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Test Type

• Imaging Tests
• Biopsy
• Lumbar Puncture
• Molecular Testing
• Electroencephalography (EEG)
• Others

On the basis of test type, the Europe brain cancer diagnostic market is segmented into imaging tests, biopsy, lumber puncture, molecular testing, electroencephalography (EEG), and others.

Cancer Type

• Acoustic Neuroma
• Astrocytomas
• Glioblastoma Multiforme
• Meningiomas
• Oligodendroglioma
• Others

On the basis of cancer type, the Europe brain cancer diagnostic market is segmented into acoustic neuroma, astrocytomas, glioblastoma multiforme, meningiomas, oligodendroglioma, and others.

Age Group

• Below 21
• 21-35
• 35-65
• 65 and above

On the basis of age group, the Europe brain cancer diagnostic market is segmented into below 21, 21-34, 35-65 and 65 and above.

End User

• Hospitals
• Specialty clinics
• Diagnostic centers and research institutes
• Ambulatory surgical centers
• Others

On the basis of end user, the Europe brain cancer diagnostic market is segmented into hospitals, specialty clinics, diagnostic centers, research institutes, ambulatory surgical centers, and others.

Europe Brain Cancer Diagnostic Market Regional Analysis/Insights   

The Europe brain cancer diagnostic market is analyzed, and market size insights and trends are provided by country, test type, cancer type, age group, and end user.

The Europe brain cancer diagnostic market comprises of Russia, Spain, Turkey, Germany, Italy, United Kingdom, France, Belgium, Switzerland, Netherlands, and Rest of Europe.

In 2023, Germany is expected to dominate the Europe brain cancer diagnostic market due to increasing awareness among consumers about the benefits of a brain cancer diagnosis. An increase in demand for Brain cancer diagnostics products and an increase in research and development activities in the industry are also expected to drive the market in the forecasted period.

Competitive Landscape and Europe Brain Cancer Diagnostic Market Share Analysis

The brain cancer diagnostic market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies focus on the Europe Brain cancer diagnostic market.

Some of the major players operating in this market are NIHON KOHDEN CORPORATION., Canon Inc., FUJIFILM Holdings Corporation, Neusoft Corporation, GE HealthCare, Koninklijke Philips N.V., BD, and FONAR Corp., among others.

SKU-69741